Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia (A61P1/06)

A   Human necessities(312083)
A61P1/06                     Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia(61)
ethod for treatment of irritable bowel syndrome with constipation, associated with bacterial overgrowth syndrome // 2613125
FIELD: medicine.SUBSTANCE: invention is intended for treatment of irritable bowel syndrome with constipation (IBS-C) associated with the bacterial overgrowth syndrome (BOGS). Mebeverine, 0.2 g, 2 times a day in combination with 30 ml of lactulose per day for 3 months are prescribed. Three courses of sequential therapy carried out without interruption and consisting of 0.4 g of rifaximin two times a day for 6 days, then 0.25 g of enterol 2 times a day for 10 days, then bifiform 1 capsule 2 times per day for 15 days, are prescribed simultaneously.EFFECT: method enables higher clinical effectiveness.1 tbl, 2 ex

Antibodies against tnf-α and use thereof // 2595379
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, particularly to an anti-TNF(tumour necrosis factor)-α antibody or anti-TNF-α-binding fragment antibody. Also disclosed is a pharmaceutical composition for treating pathologies and diseases associated with TNF-α, containing a therapeutically effective amount of said antibody or fragment thereof.EFFECT: invention provides effective treatment of TNF-α-mediated disease.15 cl, 6 dwg, 25 tbl, 2 ex

ethod for complex therapy of functional digestive disorders in pre-school children // 2586280
FIELD: medicine.SUBSTANCE: invention refers to medicine and is intended for functional digestive disorders treatment in preschool age children. Lactofiltrum by 1 tablet 3 times a day, 1 hour before meal, for 14 days; Trimedat by 25 mg × 3 times for 14 days; Creon 10,000 Units a day during meal for 10 days, are administered. Additionally, aqueous tincture of Moneses uniflora by 10 ml 2 times a day (morning and evening), 20 minutes after meal for 3 week course, and medical foodstuff "Bifilife" by 100 g 2 times a day (morning and evening) for 3 months, are administered.EFFECT: method can improve coprology indices and correct intestinal dysbacteriosis in out-patient treatment.1 cl, 16 tbl
ethod of treating pylorospasm following pylorus-preserving pancreatoduodenectomy // 2568889
FIELD: medicine.SUBSTANCE: Levomecol ointment 40 g with diluted 0.5% Novocaine 20 ml and 0.1% atropine 0.1 ml is administered into a stomach through a probe once a day at regular intervals during at least two days.EFFECT: method enables increasing the clinical effectiveness.1 ex

Quinoline-like compound substituted by phosphorus-containing group, method for preparing it, therapeutic composition containing this compound and using it // 2551274
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to quinolines substituted by phosphorus-containing group of formula and applicable in medicine, wherein Z represents V1 and V2 are independently specified in hydrogen or halogen; one of R and R` represent phosphorus-containing substitute Q; the other one is specified in hydrogen or methoxyl; wherein the phosphorus-containing substitute Q represents A represents O; L represents C1-6alkyl; J represents NH or C3-6heterocycloalkyl and J is optionally substituted by G3; X is absent or represents -C(=O)-; X is absent or represents C1-6alkyl; each of R1 and R2 are independently specified in C1-6alkyl or C1-6alkoxy; G3 represents C1-6alkyl, R3S(=O)m-, R5C(=O)- or R3R4NC(=O)-; R3, R4 and R5 are independently specified in 3 or C1-6alkyl; m is equal to 0-2.EFFECT: there are presented new protein kinase inhibitors effective for treating the diseases associated with abnormal protein kinase activity.20 cl, 42 ex, 8 tbl, 3 dwg

High drug load mesalazine sachet // 2547552
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to oral pharmaceutical composition in the form of a granulate produced without spheronisation. The composition contains 92-98 wt % of mesalazine or its pharmaceutically acceptable salt, 2-8 wt % of polyvinylpyrrolidone and an ethylcellulose coating, wherein the above coating weight relates to the above mesalazine weight as 0.3-1.5% and the ethylcellulose coating weight makes 0.11-0.15 mg/cm2. The granulate is packed in a sachet, a capsule or a blister. What is also described is a method for preparing a pharmaceutical composition.EFFECT: ethylcellulose-coated mesalazine granulate combines a high drug load and a desired mesalazine release profile, namely, 5-25% of released mesalazine 15 min later, 30-70% of released mesalazine 90 min later and 75-100% of released mesalazine 240 min later.10 cl, 1 ex

Using lactic acid bacilli inhibiting gas-producing coliform bacteria recovered from newborn children suffering colics // 2544054
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to industrial microbiology. The probiotic bacterial strain Lactobacillus delbrueckii MB386 deposited in DSMZ 10.12.2008 under registration No. DSM 22106 as an inhibitor of Coliform bacteria of the species Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae and Enterococcus faecalis. The pharmaceutical composition for inhibiting Coliform bacteria of the species Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter aerogenes, Enterobacter cloacae and Enterococcus faecalis containing the bacterial strain Lactobacillus delbrueckii MB386 deposited in DSMZ. An edible composition containing the bacterial strain Lactobacillus delbrueckii MB386.EFFECT: using the bacterial strain Lactobacillus delbrueckii MB386 as an ingredient of the pharmaceutical or edible composition enables inhibiting Coliform bacteria effectively.20 cl, 2 tbl, 2 dwg, 7 ex

Novel benzamide derivatives // 2536688
FIELD: chemistry.SUBSTANCE: invention relates to novel compounds, represented by formula 1, where m stands for an integer number from 1 to 5; and Q represents a heteroaromatic ring or phenyl, where the heteroaromatic ring is selected from the group, consisting of triazole, tetrazole, indole, imidazole, pyridine and pyrrole, and is independently substituted with 0, 1, 2 or 3 substituents, selected from C1-C4alkyl, C1-C4alkoxy, hydroxy and halogen, and where phenyl is independently substituted with 1, 2 or 3 substituents, selected from hydroxy and fluorine; a method of obtaining them and a 5-HT4 receptor agonist, which contains them as an active ingredient.EFFECT: obtaining the novel compounds.17 cl, 4 tbl, 24 ex

ethod of producing stabilised drotaverine hydrochloride substance // 2535049
FIELD: chemistry.SUBSTANCE: stability is achieved by crystallising drotaverine hydrochloride in the presence of a stabilising additive of a mixture of citric acid and its sodium salt in amount of up to 1.0% of the weight of drotaverine hydrochloride fed for crystallisation. In order to protect drotaverine hydrochloride from oxidative decomposition, the composition of the solution before crystallising the end product may include additional stabilising components: trilon B, sodium metabisulphite, benzethonium chloride in amount of not more than 1.0% of the weight of drotaverine hydrochloride fed for crystallisation.EFFECT: high stability during prolonged storage.2 cl, 2 ex, 1 tbl
ethod for assessing clinical effectiveness of prokinetics of various groups of patients suffering from aggravated chronic obstructive pulmonary disease // 2534412
FIELD: medicine.SUBSTANCE: invention refers to therapy and gastroenterology, and can be used to assess the effectiveness of prokinetics at a various degree of bradientery in patients with aggravated chronic obstructive pulmonary disease (COPD) receiving standard therapy, and a prokinetic or a combination of prokinetics. That is ensured by calculating an average bradientery index (index) before the beginning of the therapy and on the 11th day from the beginning of the therapy with scoring a circadian rhythm regularity of the intestinal evacuation function. If the patient has a stool 7 days a week, zero points are assigned; if he/she has a stool 5-6 days - one point is assigned; 3-4 days - two points, 1-2 days - three points. The formula index=(P0+P1+P2+P3) /Pcom, wherein P0 is the number of patients in the group having zero points, P1 - having one point, P2 - having two points, P3 - having three points; Pcom is the number of patients in the group. That is followed by calculating a bradientery manifestation coefficient Cbm by formula Cbm=(index 11 day /index 1 day)×100%, wherein index 1 day is the bradientery index before the beginning of the treatment; index 11 day is the bradientery index on the 11th day of the treatment. If Cbm makes more than 70%, then the clinical effect of the prokinetic is considered to be unpronounced. If Cbm makes 40% to 70%, the moderate manifestation of the clinical effect of the prokinetic is considered. If Cbm is less than 40%, the clinical effect of the prokinetic is considered to be adequate for the correction of the motor evacuation dysfunction of the gastrointestinal tract.EFFECT: providing the clinical assessment of the clinical effectiveness of the prokinetics of various groups, as well as enabling the selection of the most optimal preparation for the correction of the gastrointestinal motility disorders in the patients with COPD.2 tbl

Oxyindole derivatives possessing agonist activity on motilin receptor // 2533116
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to new oxyindole derivatives of formula (I) or their pharmaceutically acceptable salts, based pharmaceutical compositions and using them for treating various disorders, which are mediated through the motilin receptor (GPR38). In general formula I, R1 means hydrogen, C1-C4alkyl or C3-C7cycloalkyl; R2 means C1-C4alkyl or C3-C7cycloalkyl; or R1 and R2 together with atoms which they are bound to, form a 3-6-merous ring, which can contain oxygen; R3 and R4 mean hydrogen or C1-C4alkyl; R5 means hydrogen or C1-C4alkyl; R6 and R7 mean hydrogen, C1-C4alkyl or C1-C4alkoxy C1-C4alkyl; or R6 and R7 together with a nitrogen atom which they are bound to, form a 4-6-merous ring, which can contain nitrogen or oxygen; the 4-6-merous ring is optionally substituted by 1-4 substitutes specified in a group consisting of C1-C4alkyl, amino, C1-C4alkylamino and di(C1-C4alkyl)amino; A means or , wherein p, q and r independently have the values of 0, 1 or 2; R8 and R9 mean hydrogen or C1-C6alkyl; wherein alkyl is optionally substituted by hydroxy, C1-C4alkyl, amino, C1-C4alkylamino and di(C1-C4alkyl)amino; or R8 and R9 can be combined to form a C3-C7-merous ring; or R8 and R9 can be independently combined with one or both R8 and R9 groups to form alkylene bridges between terminal nitrogen and an alkyl part of R8 or R9 groups; the bridge contains 1 to 5 carbon atoms; the above bridge is optionally substituted by 1-4 C1-C4 alkyl groups; W means N-R10, the above R10 means hydrogen or C1-C4alkyl; X means C0-C4alkylene or C0-C4alkylene-K-C0-C4alkylene, wherein K means -O- and wherein alkylene is optionally substituted by C1-C4alkyl; Y means hydrogen or a 5-10-merous ring; the above ring is optionally substituted by hydroxyl, halogen, halogen C1-C4alkyl, C1-C4alkyl or C1-C4alkoxy; provided X means C0, Y means other than hydrogen; Z means halogen or C1-C4alkyl; m has the value of 0, 1, 2, 3 or 4; n has the value of 0, 1 or 2.EFFECT: preparing the new oxyindole derivatives.10 cl, 15 tbl, 99 ex

Gastric acid secretion-inhibiting imidazopyridine derivatives // 2509771
FIELD: chemistry.SUBSTANCE: present invention relates to organic chemistry and specifically to substituted imidazo[1,2-a]pyridines of formula I , where R is -CH2COOH or -COOH. The invention also relates to a method of producing a compound of formula I and use of the compound of formula I.EFFECT: obtaining novel substituted imidazo[1,2-a]pyridines, which inhibit exogenically or endogenically stimulated secretion of gastric acid and which can be used in preventing or treating diseases associated with gastric acid, and inflammatory gastrointestinal diseases.6 cl, 3 ex

Drug preparation in form of orally dispersible tablet and method for making drug preparation // 2503447
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine and chemical-pharmaceutical industry, namely to drug preparations used in various spastic intestinal and pancreatic-biliary conditions, especially in irritable bowel syndrome, and to methods for making them. The drug preparation in the form of an orally dispersible tablet characterised by the fact that it contains a combination of hyoscine butyl bromide and diclofenac or its sodium salt in complex with polacrilin potassium in ratio of diclofenac or its sodium salt and polacrilin potassium of 1:2, and pharmaceutically acceptable additives containing mannitol, aspartame and crospovidone. Polyvinyl pyrrolidone K30, a flavouring agent and anhydrous colloidal silicon dioxide.EFFECT: tablets have the improved bioavailability of the agent.2 cl, 4 ex

New therapeutic composition for treating pain syndrome accompanying smooth muscle spasm // 2497505
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and medicine, and represents a therapeutic composition in the form of an orally dispersed tablet for treating a pain syndrome in smooth muscle spasm characterised by the fact that it contains a combination of hyoscine butylbromide and a non-steroidal anti-inflammatory drug (NSAID) in the therapeutically effective amounts as active ingredients and pharmaceutically acceptable additives.EFFECT: invention provides the higher efficacy and improved bioavailability of the active ingredient.5 cl, 6 ex, 1 tbl, 1 dwg

Using lactobacillus paracasei cncm i-2116 to treat irritable bowel syndrome // 2490325
FIELD: chemistry.SUBSTANCE: invention relates to use of the Lactobacillus paracasei CNCM I-2116 strain to treat irritable bowel syndrome. A probiotic includes dead Lactobacillus paracasei CNCM I-2116 bacteria, a fermentation substrate and/or material made from Lactobacillus paracasei CNCM I-2116.EFFECT: invention provides the capacity to normalise post-infection hyper-contractible state of intestinal muscles.2 cl, 4 dwg, 2 ex

Therapeutic preparation 'aqueous-alcoholic solution of purified mumiyo' // 2482862
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, particularly to therapeutic preparations of mumiyo. The therapeutic preparation which contains purified mumiyo, grapefruit citrosept, edible glycerol, ethanol and water at specific proportions.EFFECT: preparation has a prolonged shelf life.8 tbl

Andrographis paniculata extract // 2468809
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, particularly an Andrographis paniculata extract for treating inflammatory bowel disease. The Andrographis paniculata extract for treating inflammatory bowel disease, containing andrographolide lactones, polysaccharides and flavonoids in certain amounts. The pharmaceutical composition for treating inflammatory bowel disease containing the Andrographis paniculata extract. A method of treating inflammatory bowel disease in a subject.EFFECT: Andrographis paniculata extract is effective for treating inflammatory bowel disease.29 cl, 4 ex
ethod for preparing for mantoux test with 2 te ppd-l in children with burdened previous allergic history // 2466730
FIELD: medicine.SUBSTANCE: in children with a suspected early period of primary tuberculosis infection and active tuberculosis infection, previously infected with tuberculosis micobacteria, the sorbent Polysorb MP is prescribed before the Mantoux test with 2 TE PPD-L: in children at the age of 1-7 years old - 1.0 g of the preparation, 7-14 years old - 2.0 g, 14 and more years old - 4.0 g three times a day for 10 days.EFFECT: more effective diagnosis of tuberculosis infection in children due to a reduced number of false-positive results.2 ex, 5 tbl
Antituberculous drug // 2466722
FIELD: medicine.SUBSTANCE: invention refers to an antituberculosis drug containing sodium aminosalicylate 2.0-14.0 g and chlorine ions 0.00020-0.00150 g.EFFECT: preparing the stable and effective antibuberculosis drug.3 ex
ethod of treating inflammatory intestinal diseases // 2463055
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating inflammatory intestinal diseases. That is ensured by the preliminary oral administration of the probiotic Bifiform 2-3 capsules a day that is followed by the 4-5 mucosal introductions of the preparation 0.5 to 1.5 ml in the changed intestinal region; the preparation is presented by Remicade and followed by the intake of the probiotic Bifiform 1 capsule 3 times a day for 3 weeks.EFFECT: method provides higher clinical effectiveness ensured by enhanced epithelial cell proliferation and improved formation of small follicles and expansion in goblet cell count in intestinal mucosa, normalisation of intestinal crypt structure.3 ex

Oxymethyluracyl and mebeverine hydrochloride pill for functional gastrointestinal diseases // 2453308
FIELD: medicine.SUBSTANCE: invention refers to medicine. The presented therapeutic agent in the form of a pill contains oxymethyluracyl and mebeverine hydrochloride as active substances, as core-coating excipients - mixed potato starch and lactic sugar in relation 1:1; mixed 5% alcohol-acetone acetyl phthalylcellulose (APC), 10% aqueous potato starch and 0.1% aqueous styrene maleic anhydride copolymer (SMAC) in relation 1:1:1 as a humidifier 1; mixed 3% aqueous Kollidon 90F, povidone and 0.1% aqueous SMAC in relation 1:1 as a humidifier 2; 5% APC as a humidifier 3; mixed 64% sugar syrup and 1% Kollidon 25 in relation 5:1 as a humidifier 4 in certain proportions.EFFECT: invention provides preparing the new therapeutic agent possessing anti-inflammatory, recycling, antispasmodic and antioxidant actions, with uniform distribution and complete enteric solubility in 2 hours, with retard action during 1 hour.4 dwg, 2 tbl, 5 ex
ethod of treating bronchial asthma // 2445082
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly pulmonology, laboratory diagnostics and immunology, and can be used for treating bronchial asthma. That is ensured by evaluating a bronchial asthma control level by GINA 2006 criteria and a related therapeutic stage; additionally, patient's peripheral blood is examined for CD 25+ antigen expressed on an membrane of activated lymphocytes by indirect immunofluorescence test, and if the CD 25+ cell level is 11 or more, then the combined therapy with iGCS and long-acting β2-antagonist is recommended.EFFECT: method ensured bronchial asthma control ensured by reflected effectiveness of the basic anti-inflammatory therapy.1 ex, 1 tbl
ethods of treating with using citrulline // 2444355
FIELD: medicine.SUBSTANCE: invention refers to medicine, and can be used for treating early satiety or other dyspepsia symptoms in a mammal suffering a chronic disease selected from a group: human immunodeficiency virus (HIV), eating disorder, such as undernutrition and/or dehydration, cancer, chronic obstructive pulmonary disease (COPD), anorexia, including age-related senile anorexia, sarcopenia, depression, Alzheimer's disease, Parkinson's disease or their combinations. That is ensured by introducing an effective amount of L-citrulline as a part of a nutritive supplement.EFFECT: invention provides clinical effectiveness in early satiety or other dyspepsia symptoms, including in ageing diseases due to relaxation of patient's smooth gastric muscles ensured by higher concentration of nitrogen oxide in cells and a substratum for maintaining a normal arginine level.9 cl, 1 tbl, 3 ex

Bacteria lactobacillus reuteri strain for making probiotic product, and probiotic product containing it // 2435844
FIELD: medicine.SUBSTANCE: invention refers to biotechnology, and concerns a lactic bacteria Lactobacillus reuteri DSM 17938 strain stimulating IL-10 production and hence CD4+CD25+TR-cell proliferation used for making a probiotic product. The probiotic product contains Lactobacillus reuteri DSM 17938 strain and additionally medium-chain triglyceride oil.EFFECT: use of the probiotic product promoted a favorable effect on intestinal colic in a newborn baby.3 cl, 3 dwg, 1 tbl, 2 ex
ethod of treating oesophageal achalasia // 2430726
FIELD: medicine.SUBSTANCE: invention refers to medicine and aimed at treatment of oesophageal achalasia. The preparation ximedone (1,2-dihydro-4,6-dimethyl,N-(β-oxyethyl)pyramidon-2) is prescribed. The preparation is taken by mouth before meals 3-4 times a day. A daily dose is 30 mg/kg of patient's weight. The course is 30 days.EFFECT: method enables stabilising contractive activity of smooth muscle fibres of an oesophageal wall.
Anti-tuberculosis medication // 2424809
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine and pharmaceutical industry, namely, to anti-tuberculosis medications for peroral application. As active substance, medication contains isoniaside in combination with para-aminosalipilate and is made in form of granules or tablets, each of which has intestine-dissoluble coating.EFFECT: increase of medication efficiency.5 cl, 2 ex
ethod of correcting functional biliary tract disorders in children with acute intestinal infections // 2419422
FIELD: medicine.SUBSTANCE: invention relates to medicine and is intended for treatment of bile passages dysfunction in children with acute intestinal infections. Used is medication Mebeverine, which is administered per os for one month after acute intestinal infection. Day dose of mebeverine constitutes for children from 3 to 4 years of age - 75 mg per day, for children from 4 to 8 years old - 150 mg per day, for children from 9 to 10 years - 300 mg per day, for children older than 10 years - 450 mg per day.EFFECT: method makes it possible to normalise indices of bile bladder function and prevent possibilities of formation of its post-infection motility disorders.2 ex

Benzene derivative substituted with 1,2-di(cyclic group) // 2407735
FIELD: chemistry.SUBSTANCE: novel compounds have general formula (1), or salts thereof: , where R10 is cyclohexyl optionally substituted with a substitute selected from group A1, or cyclohexenyl optionally substituted with a substitute selected from group A1, R30, R31 and R32 denote hydrogen, R40 denotes C1-10alkyl optionally substituted with a substitute selected from group D1, n equals 0 or 1, X1 denotes nitrogen, and R20, R21, R22 and R23 independently denote hydrogen, except when R20, R21, R22 and R23 all denote hydrogen, C1-6 alkylthio optionally substituted with a substitute selected from group F1, C2-6 alkoxycarbonyl, C1-6 alkyl substituted with a substitute selected from group W1, C1-6 alkyl substituted with a substitute selected from group K1, C1-6 alkoxy substituted with a substitute selected from group W1, a 5-6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or S atoms, substituted with a substitute selected from W1, a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or S atoms, substituted with a substitute selected from group V1, pyridyl substituted with a substitute selected from group W1, phenyl,optionally substituted with a substitute selected from group W1, C2-7 alkenyl, optionally substituted with a substitute selected from group W1, C2-7 alkynyl optionally substituted with a substitute selected from group W1, a 3-6-member cycloalkyl optionally substituted with a substitute selected from group W1, a 5-6-member cyclalkenyl optionally substituted with a substitute selected from group W1, NR1XR2X, -CO-R1X, -CO-NR1XR2X, -NR1X-CO-R2X, -SO2-R3X or -O-SO2-R3X,where R1X is hydrogen or a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N and O atoms, R2X is a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or O atoms, and R3X is C1-6 alkyl optionally substituted with a substitute selected from group F1; or R21 and R22 together form a ring selected from group Z1, where group A1 consists of C1-6 alkyl, group D1 consists of cyclopropyl and tetrahydropyranyl, group F1 consists of a halogen, group W consists of hydroxyl, C2-7 alkoxyalkyl, phenoxy, C2-7 alkoxycarbonyl, -NR6XR7X and -CO-NR6XR7X, where R6X and R7X independently denote hydrogen or C1-6 alkyl, group V1 consists of oxo (=O) and ethylenedioxy(-O-CH2CH2-O-), where ethylenedioxy is allowable only if a compound of two rings with one common atom forms together with a substituted 6-member heterocyclic group, group K1 consists of a 6-member heterocyclic group which is a non-aromatic saturated ring containing one or two heteroatoms selected from N or O atoms, group U1 consists of carboxyl, C1-6 alkoxy, phenyl and CO-NR8XR9X, where R8X and R9X denote hydrogen, and group Z1 consists of , where R1Z denotes C1-6 alkyl or benzyl. The invention also pertains to a medicinal agent, a cell adhesion or cell infiltration inhibitor, as well as to therapeutic or prophylactic agents.EFFECT: obtaining novel biologically active compounds having cell adhesion or cell infiltration inhibiting activity.20 cl, 147 ex, 3 tbl

Substituted 4-phenyltetrahydroisoquinolines, preparation method, application as medicinal agents, and also medicinal agents containing them // 2398766
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds of formula I , where: R1, R2, R3 and R4 independently from each other mean hydrogen, F, CI, Br, I; R5 designates hydrogen, alkyl with 1, 2, 3, 4, 5 or 6 C atoms, or cycloalkyl with 3, 4, 5 or 6 C atoms; R6 designates hydrogen; R7 and R8 independently from each other mean hydrogen, W means CrH2r or CsH2S-2; and one or more CH2-groups in C2H2r and CsH2s-2 can be substituted with NR17, oxygen or S; R17 means hydrogen, alkyl with 1, 2, 3 or 4 C atoms; r means 1, 2, 3, 4, 5 or 6; s means 2, 3 or 4; X designates-with C(O)- or -S(O)2-; Z means -C(O)- or a bond; and also to their pharmaceutically acceptable salts and trifluoroacetates. The invention also concerns application of the compounds of formula I, and also to a pharmaceutical composition.EFFECT: preparation of new biologically active compounds exhibiting NHE3 inhibiting activity.16 cl, 64 ex, 1 tbl
ethod of treating threatened miscarriage in early pregnancy // 2393841
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to obstetrics. The method involves preliminary preferred position of placenta aspect. The pregnant women on their 1-2 trimester of pregnancy suffering disordered uteroplacental hemodynamics are prescribed with transdermal exposure to deponite-10. The exposure involves an acupuncture point BM-147 of the leg corresponding to the placenta side and lasts for 12-24 hours. The therapeutic course is 1-2 sessions. The therapeutic course is 1-2 sessions.EFFECT: method reduces medicament load on a body of the pregnant woman.2 ex

Phenoxyalkyl carbonic acids derivative in treatment of inflammatory diseases // 2388466
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, particularly, to urology and gastroenterology and concerns treatment of interstitial cystitis or irritable colon syndrome (adaptive colitis) or ulcerative colitis using phenoxyalkyl carbonic acids derivatives. The effective quantity of compound 1: or of its metabolite - compound 2:or pharmaceutically acceptable salts thereof, or pro-drug forms, is administered to the patient.EFFECT: invention ensures high therapeutic efficacy in treatment of the specified diseases due to simultaneous action of the compounds on a number of chemical inflammation mediators.23 cl, 10 tbl, 10 ex, 5 dwg
Rectal mudtherapy // 2377001
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to physiotherapy. Pre-homogenised medical mud of Tambukan lake is placed in a light- and gas-tight enclosure. Used mud contains mud solution, crystal skeleton and colloid complex at the following ratio of specified ingredients (wt %): crystal skeleton 15.0-25.0, colloid complex 10.0-20.0, mud solution - the rest. The enclosed medical mud is heated to temperature 37-40°C. Then with a syringe, the mud is slowly introduced into rectum of the patient. After introduction of the medical mud, the patient is pronated. Then 10÷20 minutes later, the patient is positioned edgewise. The mud tampon is left in rectum till urge to defecate. The procedures are performed every second day, or 2 days running with one day of break.EFFECT: method improves clinical effectiveness and provides stable and prolonged remission of intestinal diseases owing to preparation of the mud applied.7 cl, 5 ex, 1 tbl

Application of methyl naltrexone for treating irritable colon syndrome // 2373936
FIELD: medicine.SUBSTANCE: group of inventions concerns medicine and aims at treating irritable colon syndrome. The pharmaceutical preparation containing methyl naltrexone is introduced to the medically indigent patient. Said pharmaceutical preparation contains methyl naltrexone, an agent for treating irritable colon syndrome, a pharmaceutically acceptable carrier. A treatment kit contains a package with the preparation of methyl naltrexone and application instructions of the preparation of methyl naltrexone for treating irritable colon syndrome.EFFECT: invention enables beneficial effect on segmentation and intestinal peristalsis thereby providing controllability of intestinal contractile force.103 cl, 5 ex, 1 dwg

Imidazopyridine compound // 2373206
FIELD: chemistry.SUBSTANCE: invention relates to 5-methoxy-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-6-methyl-3H-imidazo[4,5-b]pyridine or to its salt, as well as a pharmaceutical composition which inhibits secretion of gastric acid based on the said compound. Description is given of production of the new compound and a pharmaceutical composition based on the new compound, which can be used in medicine for treating such diseases as gastric ulcer, duodenal ulcer, stomal ulcer, gastroesophageal reflux, Zollinger-Ellison syndrome, symptomatic gastroesophageal reflux, endoscopy negative gastroesophageal reflux, gastroesophageal regurgitation, pharyngolaryngeal paresthesia, Barrett's esophagus, Non-steroidal anti-inflammatory drug (NSAID) induced ulcer, gastritis, gastric hemorrhage, gastrointestinal hemorrhage, peptic ulcer, bleeding ulcer, stress ulcer, gastric hyperchlorhydria, dyspepsia, gastroparesis, senile ulcer, intractable ulcer, heartburn, bruxism, stomach ache, heavy stomach or erosive gastritis.EFFECT: increased effectiveness of composition and disease treatment.7 cl, 6 tbl, 29 ex
ethod of functional dyspepsia treatment // 2365367
FIELD: medicine; gastroenterology.SUBSTANCE: method includes standard medicamental therapy. Antidepressant Fevarin administration is carried out in addition, within 8 weeks, taking into account specific features of an affection condition. Fevarin is administered in a dose of 150 mg at clinically expressed affective disorders. Fevarin is administered in a dose of 100 mg a day at the subclinical expressed affective disorders. The magnetic-laser puncture with a 1.3 microns wavelength in the modulated regimen with frequency of 2.4 Hz, 50 mT magnetic field strength is carried out within 10-30 seconds on each biologically active point. The GI 4 point is sedated and the points E 25, E 36, MC 6 are toned up consistently at sympathicotonia. The GI 4 point is toned up and the points E 25, E 36, MC 6 are sedated consistently at vagotonia.EFFECT: reduction of terms of treatment, elongation of remission terms, decrease of relapses frequency at the expense of correction of a condition of daily chrono biological rhythms, psychoemotional sphere and vegetative balance.2 cl, 1 tbl, 1 ex

Atropoisomers of 3-substituted-4-arylquinoline-2-on derivatives // 2352563
FIELD: chemistry.SUBSTANCE: invention relates to novel atropoisomers of formula , in which R and R1 each independently represents hydrogen or methyl; R2, R3 and R4 each independently represents hydrogen or trifluoromethyl, on condition that R2, R3 and R4 all do not represent hydrogen; and R5 represents bromine, chlorine; or to its non-toxic pharmaceutically acceptable salt, solvate. Invention also relates to pharmaceutical composition, as well as to method of treatment.EFFECT: obtaining novel biologically active compounds, possessing properties which open calcium-activated potassium channels of high conductivity.12 cl, 6 ex, 2 tbl, 7 dwg

Probiotics for intestine neuromuscular function // 2346036
FIELD: chemistry; biochemistry.SUBSTANCE: lactobacillus paracasei CNCM 1-2116 strain is used for preventing or treating neuro-muscular disorders of intestines, caused by infection of intestines by pathogens. Such disorders are associated with, for example, spasmodic pain in the stomach (colic) in infants, pain in the intestines or discomfort in the intestines in general. The Lactobacillus paracasei CNCM 1-2116 strain is used for preventing or treating intestinal complications after infection of intestines by pathogens. The probiotic contains dead bacteria, fermentive substrate and/or material obtained from Lactobacillus paracasei CNCM 1-2116.EFFECT: achieving beneficial effects due to direct effect on contractibility of muscles.4 cl, 3 dwg, 2 ex

Application of compoundings, effective as selective opiate receptor modulators // 2336871
FIELD: medicine.SUBSTANCE: application of asimadolin or its pharmaceutically acceptable sals is proposed for preparation of pharmaceuticals for indigestion treatment: gastroparesis, gastroatonia, gastroparalysis and the digestive tract stenosis in particular. Medication is effective for tonus modulating of the digestive tract, satiation. Registered, that asimadolin (N-methyl-N-[(1S)-1-phenil-2-((3S)-3-hydroxipyrrolidin-1-il)ethyl]-2,2-dyphenylacetylene (EMD 61753), a selective modulator of the opiate kappa-receptors) depending on the dose, contributes to consumed food volume increase without afterdinner symptoms: bloat, nausea, pain after meal.EFFECT: creation for effective medication for tonus modulating of digestive tract, satiation.8 cl, 5 dwg, 4 tbl

Composition of large intestine release // 2327446
FIELD: medicine.SUBSTANCE: invention describes prednisolone metasulfobenzoate composition of controlled released within large intestine, containing sodium prednisolone metasulfobenzoate, hyaloid amylase coated, ethylcellulose and dibutyl-sebacate with ratio amylase to ethylcellulose 1:3.5 to 1:4.5, and amylase is wheat or corn amylase. Method of composition making is provided as well.EFFECT: directed released of sodium prednisolone metasulfobenzoate in large intestine at low systemic action and no systemic by-effects.12 cl, 2 dwg, 6 ex
ethod of cardiospasm medical treatment // 2325919
FIELD: medicine.SUBSTANCE: invention refers to medicine, specifically to gastroenterology and surgery and concerns cardiospasm medical treatment. For this purpose affected and abnormal areas of mucous and submucous membrane of oesophagus in oesophageal-cardial transition are endoscopic injected with agent consisting of alloplant-stimulator of connective tissue regeneration, alloplant-stimulator of phagocytosis, and stimulator of nervous structure regeneration (SNSR). To make SNSR subcortical structures are taken from allogenic donor cerebrum, rinsed in physiologic saline, frozen in cryogenic chamber and lyophilised under vacuum. Components proportion in finished agent mass %: biomaterial alloplant - stimulator of connective tissue regeneration 35-45, biomaterial alloplant - stimulator of phagocytosis 35-45, stimulator of nervous structure regeneration 10-30. Affected areas are injected in 3-7 points dosed 1-2 ml to each point. Treatment is carried out by courses in number 2-10 with intervals 1-3 weeks. Method provides complex effect on reparative regeneration of blood vessels, nerve endings and nerve fiber, causing normalisation of metabolism processes in affected area and restoration of functional activity of oesophagus.EFFECT: normalisation of metabolism processes in affected area and restoration of functional activity of oesophagus.2 ex

7-carboxymethyloxy-3',4',5-trimethoxyflavone monohydrate and methods of preparation and application thereof // 2302416
FIELD: synthesis of biologically active compounds.SUBSTANCE: invention relates to 7-carboxymethyloxy-3',4',5-trimethoxyflavone monohydrate, which is non-hygroscopic product exhibiting protective activity relative to mucous membrane of gastrointestinal tract, including large intestine, as well as methods for preparation of this compound and pharmaceutical composition based thereon. Compound of invention has such advantages as mucosa-protection activity, handling easiness, and storage ability under humidity conditions because of lack of hygroscopicity, and constant activity allowing preparation of therapeutical composition in any moment when necessary. Preparation procedure is performed under mild conditions owing to elimination of methylation step under autoclave conditions.EFFECT: enabled mass production of 7-carboxymethyloxy-3',4',5-trimethoxyflavone monohydrate without need in purification such as recrystallization or column chromatography.15 cl, 5 dwg, 5 tbl, 3 ex
Preparation for maintenance therapy of gastro-intestinal diseases in case of prolonged antibacterial treatment // 2302254
FIELD: chemical-pharmaceutical industry.SUBSTANCE: the suggested preparation contains sweet flag, perforated St.John's wort, common calendula, common yarrow, purple ecchinacea. Decoction should be prepared upon water passed through silver electrodes. The innovation provides decreased side reactions from anti-tuberculosis preparations of toxico-allergic character applied during prolonged period of time.EFFECT: higher efficiency.2 ex

Derivatives of imidazole modulating sodium channel // 2296565
FIELD: organic chemistry, medicine.SUBSTANCE: invention relates to a novel using to compounds of the general formula (I): . Also, invention relates to preparing a medicinal agent used for modulating sodium channels and, in particular, in treatment of pain (for example, neuropathic pain), epilepsy, neurodegenerative states and bipolar states.EFFECT: valuable medicinal properties of compounds.10 cl, 18 ex
ethod for predicting acute appendicitis in pregnant women // 2293561
FIELD: medicine, surgery, surgical gynecology.SUBSTANCE: one should perorally introduce xymedon at the dosage of 0.5 g to be repeated in 30 min. Then, intravenously one should inject 30 ml provocation-diagnostic curative composition, not more, that consists of aqueous solution of nicotinic acid and polyglucin taken at the following ratio of components, weight%: nicotinic acid 0.05-0.1, polyglucin 0.1-1.8, water - the rest. In case of pain one should diagnose appendicitis. The innovation provides the decrease of incorrect diagnostics in case of acute appendicitis in pregnant women at earlier stages of development along with normalizing action upon gravid uterus.EFFECT: higher accuracy and efficiency of diagnostics.1 ex, 1 tbl

Derivatives of n-triazolylmethylpiperazine, method for their preparing, medicinal agent, derivatives of piperazine // 2288918
FIELD: organic chemistry, chemical technology, medicine, pharmacy.SUBSTANCE: invention describes novel derivatives of N-triazolylmethylpiperazine of the general formula (I): , wherein R1 means hydrogen atom or (lower)-alkyl; R2 means (lower)-alkyl, di-(lower)-alkylamino-(lower)-alkyl, (lower)-alkoxycarbonyl-(lower)-alkyl, cycloalkyl with 5-6 carbon atoms in cycle, pyridinyl-(lower)-alkyl, possibly bi-substituted phenyl-(lower)-alkyl, phenyloxy-(lower)-alkyl substituted with halogen atom in phenyl ring; R3 means (lower)-alkyl, (lower)-alkyloxycarbonyl-(lower)-alkyl or (C5-C6)-cycloalkyl, or both R2 and R3 in common with nitrogen atom to which they are bound form substituted pyrrolidine ring or cyclic group of the formula (a): , wherein A means nitrogen, oxygen atom, methylene or methylidene group wherein its double bond is formed in common with adjacent carbon atom at position 3 of the group (a), and if A means nitrogen atom then this nitrogen atom has substitute R4', and in this case n means 2 or 3, and R4' means (lower)-alkyl, possibly substituted phenyl-(lower)-alkyl, possibly substituted pyridyl, pyridyl-(lower)-alkyl, (lower)-alkoxycarbonyl-(lower)-alkyl, pyrimidyl-(C5-C6)-cycloalkyl, (C5-C6)-cycloalkyl-(lower)-alkyl or morpholinyl-(lower)-alkyl; R4 and R5 mean hydrogen atom and in all cases n means a whole number from 1 to 2; R4 means hydrogen atom, (lower)-alkyl, (lower)-alkoxy-(lower)-alkyl, (lower)-alkoxycarbonyl, (lower)-alkoxycarbonyl-(lower)-alkyl, di-(lower)-alkylamino-(lower)-alkyl, phenyl, pyrrolidinyl, pyrrolidinyl-(lower)-alkyl, pyridyl or piperidinyl, cyclohexyl, cyclohexyl-(lower)-alkyl, phenyl-(lower)-alkyl, pyridyl monosubstituted with (lower)-alkyl, phenyl-(lower)-alkyl monosubstituted with (lower)-alkyl, pyrimidyl, pyridyl-(lower)-alkyl, morpholinyl-(lower)-alkyl; R5 means hydrogen atom, (lower)-alkyl or (lower)-alkoxy-(lower)-alkyl, or R4 and R5 taken in common mean spiroethylenedioxy-group bound with carbon atom of the group (a), (C3-C4)-alkylene bound with two adjacent atoms of the group (a) or phenyl anellated by two adjacent carbon atoms of the group (a), and their physiologically acceptable acid-additive salts also. Also, invention relates to methods for synthesis of these compounds, a medicinal agent based on thereof and intermediate compound in synthesis of novel compounds. Novel compounds are antagonists of neurokinin receptors and display effect in peripheral region preferably and can be used in treatment of functional and inflammatory disorders of digestive tract.EFFECT: improved preparing method, valuable medicinal properties of derivatives.10 cl, 4 tbl, 4 ex
ethod for treating dyspepsia with cholinolytics // 2284186
FIELD: medicine, gastroenterology.SUBSTANCE: the present innovation deals with treating dyspepsia with preparations of cholinolytic action. For this purpose, it is necessary to form a group of patients with the best results after applications of cholinolytics by applying, moreover, as the criterion for evaluation the following clinical signs: attack-like pains in stomach, nausea, heartburn or acid eructation, meteorism or tendency for diarrhea; in case of availability of all mentioned signs in patients the application of cholinolytics should be advised, and in case of the absence of these signs or the availability of constipations or oral dryness the application of cholinolytics should not be recommended. The innovation provides efficient therapy of dyspepsia due to prescribing cholinolytics for those patients only for whom this kind of therapy is being the most advisable.EFFECT: higher efficiency of therapy.2 ex
Spasmolytic agent // 2281100
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to a spasmolytic agent. A spasmolytic agent comprises drotaverine hydrochloride and etaverine hydrochloride. Invention provides preparing the preparation eliciting the high spasmolytic activity that is higher as compared with that of the expected total activity of drugs used.EFFECT: enhanced effectiveness and valuable medicinal properties of agent.3 tbl, 2 ex
ethod for treating enteralgia in calves // 2260433
FIELD: veterinary science.SUBSTANCE: one should inject medicinal mixture of novocain solution of 0.5% concentration, taken at the dosage of 1 ml/kg body weight and 300000 U streptomycin intraperitoneally. The method provides prophylaxis of relapses and complications of enteralgia.EFFECT: higher efficiency of therapy.4 ex, 4 tbl

ethod for treating gastroesophageal reflux disease // 2258519
FIELD: medicine, surgery.SUBSTANCE: during gastroscopy one should introduce about 10-20 ml of 1%-hydrogen peroxide solution into submucous space of esophago-gastric transition into points located at positions of 12 and 6 o'clock and about 10-20 ml of alcoholic-novocaine mixture into a point located at position of 3 o'clock. One should perform repeated procedure 10 d later: one should introduce 10-20 ml of 1%-hydrogen peroxide solution into points located at positions of 3 and 9 o'clock. The innovation provides partial restoration of muscular cardiac sphincter due to capacity of low-concentrated hydrogen peroxide solution to increase tissue viability and development of fibrous cuff that restricts the prolapse of gastric mucosa.EFFECT: higher efficiency of therapy.4 dwg, 2 ex

New derivatives of cyclic amide // 2257384
FIELD: organic chemistry, medicine, pharmacy.SUBSTANCE: invention relates to new derivatives of cyclic amide of the formula (I) or its salt, or hydrate, or solvate wherein X represents (C1-C6)-alkyl, (C1-C6)-alkyl substituted with phenyl, (C2-C6)-alkenyl substituted with phenyl or halogenphenyl, (C2-C6)-alkynyl substituted with phenyl, phenyl that can be substituted with (C1-C6)-alkyl; one or more halogen atom, nitro-group, phenyl, (C1-C6)-alkoxy-group, halogen-(C1-C6)-alkyl, halogen-(C1-C6)-alkoxy-group, phenyl-(C1-C6)-alkyl, (C1-C6)-alkoxyphenyl-(C1-C6)-alkyl, amino-group, optionally substituted with (C1-C6)-alkyl, acetyl, (C1-C6)-alkoxy-group, substituted with phenyl, phenylcarbonyl, furanyl; 1- or 2-naphthyl, monocyclic (C3-C8)-cycloalkyl, amino-group substituted with one or more substitutes taken among phenyl, halogenphenyl, (C1-C6)-alkoxyphenyl, (C1-C6)-alkyl, halogen-(C1-C6)-alkyl, phenyl-(C1-C6)-alkyl; 5- or 6-membered monocyclic heterocyclic group comprising 1 or 2 heteroatoms, such as nitrogen (N), oxygen (O), sulfur (S) atom optionally substituted with halogenphenyl, halogen atom, benzyl, (C1-C6)-alkyl, phenyl; 8-10-membered bicyclic heteroaryl group comprising 1 or 2 heteroatoms taken among N, O and optionally substituted with halogen atom; 8-10-membered polycyclic cycloalkyl group; Q means -CH2-, -CO-, -O-, -S-, -CH(OR7)- or -C(=NR8)- wherein R7 means hydrogen atom (H), (C1-C6)-alkyl; R8 means OH, (C1-C)-alkoxy-group, acylamino-group, (C1-C6)-alkoxycarbonylamino-group, phenyl-(C1-C6)-alkoxy-group; n = 0-5; B represents group or wherein each among R3, R4, R5 and R6 represents independently substitute taken among group consisting of hydrogen atom (H), halogen atom, NO2 (nitro-group), (C1-C6)-alkoxy-group, CN (cyano-group); m = 1 or 2; ring represents 5- or 6-membered aromatic heterocyclic ring comprising one or two heteroatoms taken among O, S, N. Compound of the formula (I) elicit activity inhibiting binding sigma-receptors that allows their using as component of medicinal agent.EFFECT: valuable medicinal properties of compounds.21 cl, 2 sch, 4 tbl, 183 ex
 
2551205.
Up!